NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657192/Yondelis-Ovarian-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020" provides Yondelis sales forecasts for EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for EU5

- Analysis and review of Yondelis including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Yondelis including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecasts for 2009-2020 for Yondelis in EU

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 4

2.1 Ovarian Cancer 4

2.2 Ovarian Cancer Market 4

2.3 Epidemiology 4

2.4 Etiology 6

2.4.1 Age 6

2.4.2 Inherited Gene Mutations 6

2.4.3 A Previous Cancer Diagnosis 6

2.4.4 Early Menstruation or Late menopause 7

2.4.5 Family History of Ovarian Cancer 7

2.5 GlobalData Market Forecasts Report Guidance 7

3 Ovarian Cancer: Market Characterization 8

3.1 Ovarian Cancer Market 8

3.2 Ovarian Cancer Market Forecasts and CAGR 8

3.3 Drivers for Ovarian Cancer Market 9

3.3.1 High Incidence 9

3.3.2 High Mortality Rate 10

3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11

3.3.4 Emergence of Targeted Drugs 11

3.3.5 Recurrence of Tumor 11

3.3.6 Low Initial Diagnosis Rate 11

4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12

5 Yondelis (trabectedin) 15

5.1 Introduction 15

5.2 Mechanism of Action 15

5.3 Clinical Studies 15

5.4 Approval History of Yondelis 16

5.5 Factors Affecting Sales of Yondelis 16

5.5.1 Yondelis/Doxil Combination 16

5.5.2 Increasing Competition 16

5.5.3 Adverse Events 16

5.5.4 Licensing in Japan 17

5.5.5 Rejection by NICE in the UK 17

5.6 Drug Evaluation 17

5.6.1 Drug Risk Benefit Score 17

5.6.2 Intensity of Competition 18

5.7 Sales Forecasts 18

5.7.1 Target Patient Pool of Yondelis 18

5.7.2 Dosing 19

5.7.3 Market Penetration 19

5.7.4 Annual Cost of Therapy 20

5.7.5 Sales Projections of Yondelis 21

6 Ovarian Cancer Market: Appendix 28

6.1 Market Definitions 28

6.2 List of Abberiviations 28

6.3 Research Methodology 28

6.3.1 Coverage 28

6.3.2 Secondary Research 29

6.3.3 Forecasting 29

6.3.4 Number of Patients Approved to take the Drug 29

6.3.5 Net Penetration of Drug 30

6.3.6 Net Annual Dosing 31

6.3.7 Annual Cost of Therapy 31

6.3.8 Primary Research 31

6.3.9 Expert Panels 31

6.4 Drug Sales Estimates Model 31

6.5 Contact Us 32

6.6 Disclaimer 32

6.7 Sources 32

List of Tables

Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030 6

Table 2: Detailed TNM Classification 13

Table 3: Phase III Clinical Study Results for Yondelis in Ovarian Cancer 16

Table 4: Approval History of Yondelis 16

Table 5: Drug Risk Benefit Score of Yondelis 17

Table 6: Yondelis, Ovarian Cancer, Annual Cost of Therapy ($), 2011 20

Table 7: Yondelis, Ovarian Cancer, EU-5, Sales Estimates ($m), 2009–2020 21

Table 8: Yondelis, Ovarian Cancer, The UK, Sales Estimates ($m), 2009–2020 22

Table 9: Yondelis, Ovarian Cancer, France, Sales Estimates ($m), 2009–2020 23

Table 10: Yondelis, Ovarian Cancer, Germany, Sales Estimates ($m), 2009–2020 24

Table 11: Yondelis, Ovarian Cancer, Italy, Sales Estimates ($m), 2009–2020 25

Table 12: Yondelis, Ovarian Cancer, Spain, Sales Estimates ($m), 2009–2020 26

List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5

Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030 9

Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030 10

Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030 10

Figure 6: Broad Classification of Ovarian Cancer 12

Figure 7: Classification of Ovarian Cancer 14

Figure 8: Drug Model Diagram of Yondelis 19

Figure 9: Yondelis, Ovarian Cancer, EU-5, Sales Estimates ($m), 2009–2020 21

Figure 10: Yondelis, Ovarian Cancer, The UK, Sales Estimates ($m), 2009–2020 22

Figure 11: Yondelis, Ovarian Cancer, France, Sales Estimates ($m), 2009–2020 23

Figure 12: Yondelis, Ovarian Cancer, Germany, Sales Estimates ($m), 2009–2020 24

Figure 13: Yondelis, Ovarian Cancer, Italy, Sales Estimates ($m), 2009–2020 25

Figure 14: Yondelis, Ovarian Cancer, Spain, Sales Estimates ($m), 2009–2020 26

Figure 15: Yondelis, Ovarian Cancer, EU-5, Sales Distribution (%), 2019 27

Figure 16: Drug Model Diagram 30

Figure 17: Patients Approved for the Drug 30

To order this report:

Pathology Industry: Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com